Home › Retinitis Pigmentosa › NCT04278131
BS01 in Patients With Retinitis Pigmentosa
RecruitingPhase 1/2
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Confirmed diagnosis of retinitis pigmentosa * At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°. Exclusion Criteria: * Prior receipt of any AAV gene therapy product * Large amplitude nystagmus
About the study
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
What is being tested
- BS01 (drug)
Sponsor: Bionic Sight LLC · Participants: 20 · Started: Feb 6, 2020
Contact the study team
Official record on ClinicalTrials.gov — NCT04278131
Locations in the U.S.
| New Jersey | New Jersey Retina, Teaneck |
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.